Alta Life Sciences invests in Inbiomotion

The investment was made via Alta Life Sciences Spain I, a vehicle managed by Altamar Private Equity. The fund invests in the biotechnology, biopharma, medical devices, diagnostics, genomics and digital health industries. It usually leads seed, series-A and series-B funding rounds.

Existing investors, including Institut Català de Finances (ICF), also took part in the financing for Inbiomotion.

The company intends to use the fresh capital to reach regulatory approval for its proprietary biomarker, and start commercialisation next year.

Previous funding
Spanish life-sciences-dedicated firm Ysios Capital led a €2m series-A round for Inbiomotion, through its Ysios BioFund I fund, in July 2012. Fundació Vila Casas and JVRisk Technologies also participated in the round.

In March 2016, Caixa Capital Risc led a €2.2m series-B round for Inbiomotion, investing via Caixa Innvierte BioMed II fund. Existing investors Ysios Capital and Fundación Vila Casas also contributed to the round.

Company
Founded in 2010 as a spinout from research institutions IRB Barcelona and ICREA, Inbiomotion specialises in developing a single gene-based biomarker test for predicting responses to bisphosphonates in breast cancer. This helps personalise the adjuvant treatment of early-stage breast cancer and prevent metastasis.

People
Inbiomotion – Roger Gomis (founder).
Alta Life Sciences – José Antonio Mesa (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Venture
• Spain